FuelCell Energy, Nextpower, Wabash, Avis Budget Group, and Novanta Shares Skyrocket, What You Need To Know
Shares of FuelCell Energy, Nextpower, Wabash, Avis Budget Group, and Novanta surged in the morning session after weaker-than-expected US employment data led to a cool-down in Treasury yields. The Bureau of Labor Statistics reported that nonfarm payrolls rose by only 29,000 in September, significantly below the projected 84,000, causing a slump in Treasury yields as expectations for a Federal Reserve rate hike diminished. FuelCell Energy, specifically, saw a 6.8% jump and is up 118% year-to-date, partially due to an "Outperform" rating from Oppenheimer.
Novanta (NASDAQ:NOVT) Stock Breaks Below Fifty Day Moving Average - Time to Sell?
Novanta (NASDAQ:NOVT) stock recently fell below its 50-day moving average, trading at $143.58 against an average of $147.16. Despite this technical dip, analysts maintain a "Buy" rating with an average target price of $194, supported by the company exceeding recent quarterly earnings and revenue expectations. Institutional investors hold a significant portion of the stock, with many increasing their positions, indicating continued confidence.
A Look at Novanta Inc (NOVT) After 7.3% Gain -- GF Value $156.35 vs Price $144.17
Novanta Inc (NOVT) saw its shares rise 7.3% to $144.17, placing it 7.8% below its estimated GF Value™ of $156.35, suggesting it is undervalued. The company holds a strong GF Score™ of 88/100, driven by high valuation and momentum scores, despite a lower growth rating. While gurus are generally positive, insider selling without buying activity raises a cautionary flag for investors.
Novanta Jumps 5.1% Amid Sector-Wide Rally
Novanta Inc. (NOVT) surged 5.1% to close at $141.16 on Tuesday, driven by a broad sector-wide rally among scientific and technical instruments makers. This movement is attributed to coordinated buying across the sector, rather than company-specific news, suggesting investor confidence in the industrial technology market. The gains reflect broader market sentiment and potential repositioning by institutional investors, with strong demand trends in markets like medical devices and robotics.
Is Novanta (NOVT) A Bargain Following Strong Growth And Demand Outlook?
This article analyzes Novanta (NOVT) stock, highlighting a split sentiment among investors. While many believe the stock is undervalued with a fair value of $194.50 due to its growth profile and strategic acquisitions, others view it as expensive given its high P/E ratio of 81.5x compared to industry averages. The piece encourages further analysis to weigh the potential rewards and warning signs before making investment decisions.
California State Teachers Retirement System Increases Stock Position in Novanta Inc. $NOVT
The California State Teachers Retirement System increased its stake in Novanta Inc. by 0.3% in the second quarter, now owning 41,758 shares valued at approximately $6.77 million. Other institutional investors like Bamco Inc. NY and William Blair Investment Management LLC also made significant investments. Novanta reported strong Q2 earnings, beating analyst estimates for both EPS and revenue, and has a "Buy" consensus rating from analysts with a target price of $194.00.
Novanta director Thomas Secor sells $97,858 in stock
Novanta director Thomas N. Secor sold 663 shares of the company's common stock for a total of $97,858 on September 11, 2026, as part of a pre-established trading plan. Despite the stock declining approximately 6% over the past week and appearing overvalued according to InvestingPro analysis, Novanta recently surpassed Q2 2026 earnings and revenue expectations, leading to an increased financial outlook. Secor now directly holds 662 shares of Novanta.
Novanta (NASDAQ: NOVT) director lines up $97.9K stock sale
Novanta director Thomas N. Secor has filed a Rule 144 notice to sell 663 shares of NOVANTA INC common stock, which were acquired through restricted stock vesting on January 2, 2026. The proposed sale, valued at approximately $97,858.80, will be executed through Fidelity Brokerage Services LLC on Nasdaq. This filing provides transparency into insider stock transactions and the process for selling restricted shares.
Tidal Investments LLC Has $5.62 Million Stock Position in Novanta Inc. $NOVT
Tidal Investments LLC significantly increased its stake in Novanta Inc. (NASDAQ:NOVT) by 615.8% in the second quarter, now holding 34,631 shares valued at $5.62 million. Other institutional investors have also adjusted their positions, with institutional ownership of the company at 98.35%. Novanta recently reported strong quarterly earnings, exceeding analyst expectations, and maintains a positive outlook from analysts with an average "Buy" rating and a $194 price target.
Novanta director Thomas Secor sells $97,858 in stock By Investing.com
Novanta Inc. director Thomas N. Secor sold 663 shares of company stock for a total of $97,858 on September 11, 2026, under a pre-established trading plan. Following this transaction, Mr. Secor directly holds 662 shares. The stock has seen a recent decline, and an InvestingPro analysis suggests it may be overvalued, despite the company recently exceeding Q2 2026 earnings and revenue expectations and raising its financial outlook.
Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
Novanta Inc. announced that its Chief Financial Officer, Robert Buckley, and Chief Operating Officer of Medical Solutions, John Lesica, will present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY. The company, traded on Nasdaq under "NOVT," is a leading global supplier of core technology solutions for medical and advanced industrial original equipment manufacturers. They specialize in precision medicine and manufacturing, medical solutions, and robotics and automation.
Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
Novanta Inc. announced that its CFO, Robert Buckley, and COO of Medical Solutions, John Lesica, are scheduled to present at the Baird Global Healthcare Conference on September 15, 2026, in New York, NY. The company, a leading supplier of core technology solutions for medical and advanced industrial manufacturers, combines proprietary technology with expertise in precision medicine, manufacturing, and robotics. Novanta's common shares are traded on Nasdaq under the ticker symbol "NOVT".
Novanta Inc (NOVT) Shares Fall 3.9% -- What GF Score of 88 Tells Investors
Novanta Inc (NOVT) shares dropped 3.9% to $139.48, yet are considered "Modestly Undervalued" by GuruFocus's GF Value with a strong GF Score of 88/100. While the company exhibits high financial strength and profitability, insider selling without buying activity raises caution, despite positive sentiment from five gurus. Investors are advised to monitor performance and consider both the undervaluation and potential risks.
Here’s How Much You Would Have Made Owning Novanta Stock In The Last 10 Years
Novanta (NASDAQ: NOVT) has significantly outperformed the market over the last decade, with an annualized return of 23.93%. An investment of $100 in Novanta stock 10 years ago would now be worth $862.47, demonstrating the powerful effect of compounded returns. The company currently holds a market capitalization of $5.17 billion.
Here’s How Much You Would Have Made Owning Novanta Stock In The Last 10 Years
Novanta (NASDAQ: NOVT) has significantly outperformed the market over the last decade, with an annualized return of 23.93%. An initial investment of $100 in NOVT stock ten years ago would now be worth $862.47, highlighting the power of compounded returns.
39,140 Shares in Novanta Inc. $NOVT Acquired by Summit Creek Advisors LLC
Summit Creek Advisors LLC has acquired 39,140 shares of Novanta Inc. (NASDAQ:NOVT) worth approximately $6.35 million, making it their 19th largest position. Other institutional investors have also adjusted their stakes in Novanta, while CEO Matthijs Glastra recently sold 6,500 shares. Novanta reported strong quarterly earnings, beating estimates, and analysts maintain a "Buy" consensus rating with an average target price of $194.00.
17,392 Shares in Novanta Inc. $NOVT Bought by Diversify Advisory Services LLC
Diversify Advisory Services LLC has acquired a new stake of 17,392 shares in Novanta Inc. (NASDAQ:NOVT) during the second quarter, valued at approximately $2.45 million. Other institutional investors also increased their holdings in Novanta, which saw its stock trading down 6.9% at $157.11. The company reported strong Q2 earnings, beating analyst estimates, and has received updated "Strong Buy" and "Buy" ratings from several analysts, with an average target price of $194.00.
A Look at Novanta Inc (NOVT) After 6.9% Decline -- GF Value $154
Novanta Inc (NOVT) shares recently declined by 6.9% to $157.14, yet the stock remains 2.0% overvalued according to its GF Value™ of $154.02. Despite a strong GF Score™ of 87/100, indicating robust overall performance, the company's P/E ratio is higher than its historical median, and insiders have sold $11.5 million in shares over the past year with no buying activity. Investors are advised to consider these factors, including potential risks associated with its overvaluation and insider selling, before making investment decisions.
Federated Hermes SDG Engagement Equity Fund's Novanta Inc(NOVT) Holding History
Federated Hermes SDG Engagement Equity Fund holds 10,027.00 shares of Novanta Inc (NOVT), valued at $1.30 million, making up 1.49% of their portfolio. The initial purchase was in Q2 2026 at an average price of $129.49 per share. As of the current price of $166.57, the fund has an estimated gain of $371,801.16, representing a 28.64% return on this holding.
Oppenheimer Asset Management Inc. Buys New Stake in Novanta Inc. $NOVT
Oppenheimer Asset Management Inc. has acquired a new stake in Novanta Inc. (NASDAQ:NOVT), purchasing 35,729 shares valued at approximately $5.8 million, making institutional investors collectively own 98.35% of the company. Novanta recently exceeded quarterly earnings expectations with $0.89 EPS and $265.8 million in revenue, and has provided positive fiscal 2026 EPS guidance. Despite a CEO insider sale, analysts maintain a consensus "Hold" rating with a price target of $194.
T. Rowe Price (NOVT) discloses 6.2% beneficial stake in Novanta common stock
T. Rowe Price Associates, Inc. has disclosed a 6.2% beneficial ownership stake in Novanta Inc. (NOVN), amounting to 2,222,444 shares of common stock. The firm reported sole voting power over 2,216,715 shares and sole dispositive power over all 2,222,444 shares, while explicitly denying that the report constitutes an admission of beneficial ownership. This disclosure was made via a Schedule 13G SEC filing.
Are You Looking for a Top Momentum Pick? Why Novanta (NOVT) is a Great Choice
Novanta (NOVT) is highlighted as a strong momentum pick due to its Zacks Momentum Style Score of B and Zacks Rank of #2 (Buy). The article details NOVT's impressive short-term and long-term price performance, outperforming both its industry and the S&P 500. Additionally, positive earnings estimate revisions further support its promising outlook for investors.
Wasatch Advisors LP Has $123.30 Million Stock Position in Novanta Inc. $NOVT
Wasatch Advisors LP reduced its holdings in Novanta Inc. by 23.7% in the second quarter, now owning 759,992 shares valued at $123.3 million. Despite this, institutional investors collectively hold 98.35% of Novanta's stock. The company recently exceeded earnings estimates, reporting $0.89 per share on revenue of $265.81 million, though analyst sentiment remains cautious with a "Hold" consensus rating and a $194.00 price target.
Novanta Inc. $NOVT Shares Bought by Bank of America Corp DE
Bank of America Corp DE significantly increased its stake in Novanta Inc. (NASDAQ:NOVT) by 18.3% in the first quarter, now owning 456,241 shares valued at $53.9 million. Novanta exceeded quarterly earnings expectations with $0.89 EPS and $265.81 million in revenue, and analysts currently hold a consensus "Hold" rating with a $194 price target. CEO Matthijs Glastra also sold 6,500 shares under a pre-arranged trading plan.
Avoiding Lag: Real-Time Signals in (NOVT) Movement
This article analyzes Novanta Inc. (NASDAQ: NOVT) using AI-generated real-time signals, indicating a strong overweight bias across all time horizons. It highlights an exceptional risk-reward short setup and provides specific trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and support/resistance levels to help traders navigate NOVT's movement.
Why Novanta (NOVT) Is Up 16.7% After Q2 Results And Its Largest Medical Acquisition
Novanta Inc. (NOVT) reported strong Q2 2026 results, with sales of US$265.81 million and net income of US$12.54 million, leading to a 16.7% stock increase. The company's largest acquisition to date, Riverpoint Medical, significantly expands its medical market presence and recurring consumables business. This deal, while raising integration risks, supports Novanta's acquisition-led growth strategy, with updated 2026 revenue guidance now including Riverpoint's contribution.
Novanta (NASDAQ:NOVT) Raised to Buy at Wall Street Zen
Wall Street Zen upgraded Novanta (NASDAQ:NOVT) from "hold" to "buy" after the company exceeded quarterly expectations, reporting $0.89 EPS and $265.81 million in revenue. Despite this, the broader analyst consensus remains "Hold" with an average price target of $194.00. The stock opened at $166.37, with a market capitalization of $6.29 billion, and institutional investors own 98.35% of the company.
ETFs Investing in Novanta Inc Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Novanta Inc. (NOVT) stocks. The list is sorted by market value and includes various details for each ETF such as issuer, management style, focus, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover different market segments like mid-cap, small-cap, total market, and thematic investments in technology and robotics.
California State Teachers Retirement System Purchases 7,506 Shares of Novanta Inc. $NOVT
The California State Teachers Retirement System increased its stake in Novanta Inc. (NASDAQ:NOVT) by 22% during the first quarter, purchasing 7,506 additional shares to bring its total holdings to 41,627 shares valued at $4.9 million. This increase occurred despite Novanta's CEO selling a substantial number of shares and analysts maintaining a consensus "Hold" rating for the stock. The company reported strong second-quarter earnings and revenue, exceeding analyst estimates, and provided an upbeat outlook for the rest of the year.
Novanta Delivers Double‑Digit Growth and Margin Expansion in Second Quarter 2026
Novanta (NOVT) reported a strong second quarter of 2026, with GAAP revenue up 10% to $266 million and organic growth of 9.3%. The company saw significant profitability improvements, including a 16% increase in adjusted EBITDA to $60.7 million and a 17% rise in adjusted diluted EPS to $0.89. Analysts currently rate NOVT with a Buy, while TipRanks' AI Analyst, Spark, has a Neutral rating, noting strong fundamentals but expensive valuation and weaker near-term technicals.
NOVANTA INC 3Q 2026: Revenue $265.8M, EPS $0.3— 10-Q Summary
NOVANTA INC (NOVT) reported strong third-quarter 2026 results, with revenue reaching $265.8 million, net income of $12.5 million, and diluted EPS of $0.30. These figures represent a significant increase compared to the previous year, driven by robust performance in its Automation and Medical segments. The company's growth was fueled by demand for robotics and advanced surgery offerings, along with strategic acquisitions and continued investments in manufacturing and systems.
Earnings Flash (NOVT) Novanta Inc. Posts Q2 Adjusted EPS $0.89 per Share, Vs. FactSet Est of $0.83
Novanta Inc. (NOVT) announced its second-quarter adjusted EPS of $0.89 per share, surpassing the FactSet estimate of $0.83 per share. This financial update indicates a stronger-than-expected performance for the quarter.
Novanta stock hits 52-week high at $171.99
Novanta Inc. (NOVT) has reached a new 52-week high of $172.31, reflecting a 34.62% return over the past year and a 28.68% gain year-to-date. Despite its strong performance, InvestingPro analysis indicates the stock is currently overvalued with a P/E ratio of 109.36 and a market cap of $6.31 billion. The company recently surpassed Q2 2026 earnings and revenue expectations, raising its outlook.
Is Novanta Inc (NOVT) Overvalued After Q2 Earnings Miss? GAAP EPS $0.30, Revenue $265.8M; GF Score: 87/100
Novanta Inc (NOVT) reported strong Q2 2026 financial results with GAAP revenue up 10.3% to $265.8 million and GAAP diluted EPS of $0.30, driven by operational execution and acquisitions. Despite a slight overvaluation according to GuruFocus' GF Value, the company shows robust financial strength and profitability. However, recent insider stock sales suggest potential caution for investors.
Novanta Q2 2026 earnings: Organic growth reaches 9.3% as margins expand
Novanta (Nasdaq: NOVT) reported strong Q2 2026 results with a 10.3% year-over-year revenue increase to $265.8 million and 9.3% organic growth, the highest since Q1 2023. GAAP diluted EPS rose significantly to $0.30, and adjusted EBITDA grew 16.4% to $60.7 million, with company-wide gross and adjusted EBITDA margins expanding. The company's Q3 and full-year guidance includes the Riverpoint Medical acquisition, which is expected to be immediately accretive and increase medical end-market exposure.
GUIDANCE: (NOVT) Novanta Inc. Expects Q3 Revenue Range $300.0M - $304.0M
Novanta Inc. (NOVT) has provided its revenue guidance for the third quarter, expecting it to be in the range of $300.0 million to $304.0 million. This financial outlook offers investors insight into the company's anticipated performance for the upcoming quarter.
Earnings Flash (NOVT) Novanta Inc. Posts Q2 Adjusted EPS $0.89 per Share, vs. FactSet Est of $0.83
Novanta Inc. (NOVT) reported Q2 adjusted EPS of $0.89 per share, surpassing FactSet's estimate of $0.83. This news comes as the company also announced rising Q2 adjusted earnings and revenue, leading to a lift in its 2026 guidance. Novanta also provided Q3 revenue and adjusted EPS guidance, along with news of its recent acquisition of Riverpoint Medical, LLC.
Novanta Announces Financial Results for the Second Quarter 2026
Novanta Inc. reported strong financial results for the second quarter of 2026, with GAAP revenue increasing 10% to $266 million and Adjusted EBITDA up 16% to $61 million. The company exceeded expectations in revenue, margins, and profitability, and also announced the acquisition of Riverpoint Medical, which is expected to significantly boost its medical consumables business and overall financial performance. Novanta provided optimistic financial guidance for the third quarter and full year 2026, incorporating the contributions from the recent acquisition.
Novanta (NOVT) Tops Q2 Earnings and Revenue Estimates
Novanta (NOVT) reported strong Q2 earnings of $0.89 per share, surpassing the Zacks Consensus Estimate of $0.83, and revenues of $265.81 million, exceeding expectations by 1.64%. The company has consistently beaten EPS and revenue estimates over the past year. Despite its strong performance, Novanta currently holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market in the near future.
Novanta earnings in focus: Can bookings momentum drive growth?
Novanta Inc. is set to report its second-quarter results, with analysts expecting EPS of $0.86 and revenue of $262.3 million. Investors will be focused on whether the company can translate its strong first-quarter bookings momentum into sustained revenue growth and address margin performance concerns. The recent acquisition of Riverpoint Medical will also be a key discussion point regarding integration and enhanced growth in minimally invasive procedures.
ETFs Investing in Novanta Inc Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold stocks of Novanta Inc. The list is sorted by market value and includes various details such as issuer, management style, focus, expense ratio, assets under management (AUM), and 3-year NAV total return. The ETFs cover different market segments like mid-cap, small-cap, total market, and specific themes such as robotics and automation.
Novanta Inc Revenue Breakdown – BIVA:NOVT/N
Novanta Inc's latest financial data shows a total revenue of 17.68 B MXN. The Automation Enabling Technologies segment was the highest contributor at 9.03 B MXN, down from 10.23 B MXN the previous year. The United States remained the primary regional contributor, accounting for 9.36 B MXN.
Novanta Inc expected to post earnings of 83 cents a share - Earnings Preview
Novanta Inc is expected to announce earnings of 83 cents per share. This information is presented as an earnings preview by Refinitiv, available through TradingView News. The full article can be accessed on TradingView for those with unlimited access.
Novanta (NOVT) Reports Earnings Tomorrow: What To Expect
Novanta (NASDAQ: NOVT), a medicine and manufacturing technology provider, is set to report earnings tomorrow. The company beat revenue expectations last quarter, and analysts anticipate an 8.8% year-on-year revenue growth for the upcoming quarter. Despite some underperformance in the electronic components sector, analysts have largely reconfirmed their estimates for Novanta, with an average price target of $175.
Novanta Inc. Revenue Breakdown – NASDAQ:NOVT
Novanta Inc. (NASDAQ: NOVT) reported total revenue of $980.60 million USD last year. The Automation Enabling Technologies segment was the highest performing, generating $500.83 million USD. The United States was the largest geographical contributor, accounting for $519.01 million USD of the company's revenue.
Discipline and Rules-Based Execution in NOVT Response
This article provides an analysis of Novanta Inc. (NASDAQ: NOVT), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details specific institutional trading strategies, including long, breakout, and short positions, based on AI models and multi-timeframe signal analysis. The report identifies an exceptional risk-reward short setup and offers real-time signals and analysis for subscribers.
Novanta Completes Acquisition Of Riverpoint Medical
Novanta has acquired Riverpoint Medical from Arlington Capital Partners, a move expected to double Novanta's recurring medical consumables revenue to approximately $300 million and increase its medical end-market exposure to 60% of total revenue. The acquisition integrates Riverpoint's expertise in minimally invasive surgical consumables and IP-protected private-label products, unlocking a $2 billion incremental addressable market and enhancing Novanta's manufacturing footprint. This deal is projected to be immediately accretive to Novanta's organic growth, margins, and cash flows, with an estimated contribution of $0.18 to $0.25 adjusted earnings per share in 2027.
Discipline and Rules-Based Execution in NOVT Response
This article analyzes Novanta Inc. (NASDAQ: NOVT), highlighting a weak near and mid-term sentiment that could challenge its long-term positive outlook. AI models have generated three trading strategies: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy. The analysis includes key risk-reward metrics and multi-timeframe signal analysis, indicating strong long-term support despite current weaknesses.
Novanta Inc (NOVT) Financial Health: Profitability & Balance Sheet Analysis
Novanta Inc (NOVT) has a robust financial status with a current score of 7.33, ranking 27th in its industry. The company reported a latest quarterly revenue of $257.71 million, showing a 10.43% year-over-year increase, and a net profit increase of 0.51% year-over-year. While its operating efficiency is average, key financial metrics like cash and cash equivalents, total assets, and free cash flow were not disclosed in detail.
Novanta (NOVT) Completes Riverpoint Medical Deal To Expand Recurring Consumables Revenue
Novanta (NOVT) has completed its acquisition of Riverpoint Medical, significantly increasing its exposure to the medical consumables market and expecting to approximately double its recurring medical consumables revenue. This deal marks a shift in Novanta's business mix towards a higher share of medical end-market exposure and adds a different revenue profile alongside its existing equipment and component lines. Investors should monitor how Novanta integrates Riverpoint Medical and reports on the recurring revenue from this acquisition.
